

PRIOR AUTHORIZATION REQUEST

Bylvay

Patient Inforr	nation:			
Name:				
Member ID:				
Address:				
City, State, Zi	o:			
Date of Birth:				
Prescriber In	formation:			
Name:				
NPI:				
Phone Number	er:			
Fax Number				
Address:				
City, State, Zi	o:			
Requested M	edication			
Rx Name:				
Rx Strength				
Rx Quantity:				
Rx Frequency	:			
Rx Route of				
Administration				
Diagnosis and	I ICD Code:			
prescribed a me quantities can be Upon receipt or SECTION A requests. Pl	dication for your provided. Plea for the complete state of the com	efit requires that we review certain requests for coverage with the presentation that requires Prior Authorization before benefit coverage or coverage complete the following questions then fax this form to the toll-free number of form, prescription benefit coverage will be determined based on the that supporting clinical documentation is required or authorization reviews can be subject to trial with a state of the trial with a state of trial with a state of the trial with a state of trial with a state of the trial with a state of th	rerage of a umber liste the plan for ALL addition	dditional d below. 's rules. PA
		nts, MDH transmittals and updates to treatment guide		
		sis or indication? al Intrahepatic Cholestasis (If checked, go to 2)		
[] Oth	er (If checked, r	no further questions)		
gastı intra			Yes	No

If you have any questions, call: 1-888-258-8250

PRIOR AUTHORIZATION REQUEST

Does the patient have cirrhosis? [If yes, no further questions.] Does the patient have portal hypertension? [If yes, no further questions.] Does the patient have portal hypertension? [If yes, no further questions.] Does the patient have history of a hepatic decompensation event? [Note: Examples of a hepatic decompensation event include variceal hemorrhage, ascites, and hepatic encephalopathy.] [If yes, no further questions.] Is the patient currently receiving the requested medication? [If no, skip to question 10.] Has the patient been receiving medication samples for the requested medication? [If yes, skip to question 10.] Does the patient have a previously approved prior authorization (PA) on file with the current plan? [Note: If the patient does NOT have a previously approved PA on file for the requested medication with the current plan, the renewal request will be considered under initial therapy.] [If no, skip to question 10.] Has documentation been submitted to confirm that there is clinical response of the patient's condition which has stabilized or improved based upon the prescriber's assessment for the following: A) Decrease in serum blie acids; B) Decrease in pruritus? ACTION REQUIRED: Submit supporting documentation. [No further questions.] Is the patient 3 months of age or older? [If no, no further questions.] Does the patient have moderate-to-severe pruritus, according to prescriber? Yes No [If no, no further questions.] Was the diagnosis of progressive familial intrahepatic cholestasis include the ATPBd gene, ABCB11 gene, ABCB4 gene, TJP2 gene, NR1H4 gene, and MYO5B gene.] [If no, no further questions.]				
[If yes, no further questions.] Does the patient have history of a hepatic decompensation event? [Note: Examples of a hepatic decompensation event include variceal hemorrhage, ascites, and hepatic encephalopathy.] [If yes, no further questions.] If yes, no further questions.] Is the patient currently receiving the requested medication? [If no, skip to question 10.] Has the patient been receiving medication samples for the requested medication? [If yes, skip to question 10.] Does the patient have a previously approved prior authorization (PA) on file with the current plan? [Note: If the patient does NOT have a previously approved PA on file for the requested medication with the current plan, the renewal request will be considered under initial therapy.] [If no, skip to question 10.] Has documentation been submitted to confirm that there is clinical response of the patient's condition which has stabilized or improved based upon the prescriber's assessment for the following: A) Decrease in serum bile acids: B) Decrease in pruritus? ACTION REQUIRED: Submit supporting documentation. [No further questions.] Is the patient 3 months of age or older? [If no, no further questions.] Does the patient have moderate-to-severe pruritus, according to prescriber? Yes No [If no, no further questions.] Was the diagnosis of progressive familial intrahepatic cholestasis confirmed by genetic testing demonstrating a gene mutation affiliated with progressive familial intrahepatic cholestasis; include the ATP881 gene, ABC811 gene, ABC84 gene, TJP2 gene, NR1H4 gene, and MYO58 gene.] [If no, no further questions.]	3		Yes	No
[Note: Examples of a hepatic decompensation event include variceal hemorrhage, ascitess, and hepatic encephalopathy.] [If yes, no further questions.] 6	4		Yes	No
[If no, skip to question 10.] 7 Has the patient been receiving medication samples for the requested medication? Yes No [If yes, skip to question 10.] 8 Does the patient have a previously approved prior authorization (PA) on file with the current plan? [Note: If the patient does NOT have a previously approved PA on file for the requested medication with the current plan, the renewal request will be considered under initial therapy.] [If no, skip to question 10.] 9 Has documentation been submitted to confirm that there is clinical response of the patient's condition which has stabilized or improved based upon the prescriber's assessment for the following: A) Decrease in serum bile acids; B) Decrease in pruritus? ACTION REQUIRED: Submit supporting documentation. [No further questions.] 10 Is the patient 3 months of age or older? Yes No [If no, no further questions.] 11 Does the patient have moderate-to-severe pruritus, according to prescriber? Yes No [If no, no further questions.] 12 Was the diagnosis of progressive familial intrahepatic cholestasis confirmed by genetic testing demonstrating a gene mutation affiliated with progressive familial intrahepatic cholestasis? [Note: Gene mutations affiliated with progressive familial intrahepatic cholestasis include the ATP8B1 gene, ABCB11 gene, ABCB4 gene, TJP2 gene, NR1H4 gene, and MYO5B gene.] [If no, no further questions.]	5	[Note: Examples of a hepatic decompensation event include variceal hemorrhage, ascites, and hepatic encephalopathy.]	Yes	No
[If yes, skip to question 10.] 8	6		Yes	No
the current plan? [Note: If the patient does NOT have a previously approved PA on file for the requested medication with the current plan, the renewal request will be considered under initial therapy.] [If no, skip to question 10.] 9 Has documentation been submitted to confirm that there is clinical response of the patient's condition which has stabilized or improved based upon the prescriber's assessment for the following: A) Decrease in serum bile acids; B) Decrease in pruritus? ACTION REQUIRED: Submit supporting documentation. [No further questions.] 10 Is the patient 3 months of age or older? [If no, no further questions.] 11 Does the patient have moderate-to-severe pruritus, according to prescriber? [If no, no further questions.] 12 Was the diagnosis of progressive familial intrahepatic cholestasis confirmed by genetic testing demonstrating a gene mutation affiliated with progressive familial intrahepatic cholestasis include the ATP8B1 gene, ABCB11 gene, ABCB4 gene, TJP2 gene, NR1H4 gene, and MYOSB gene.] [If no, no further questions.] 13 Does the patient have a ABCB11 variant resulting in non-functional or complete absence of bile salt export pump protein (BSEP-3)? [If yes, no further questions.]	7		Yes	No
[Note: If the patient does NOT have a previously approved PA on file for the requested medication with the current plan, the renewal request will be considered under initial therapy.] [If no, skip to question 10.] 9 Has documentation been submitted to confirm that there is clinical response of the patient's condition which has stabilized or improved based upon the prescriber's assessment for the following: A) Decrease in serum bile acids; B) Decrease in pruritus? ACTION REQUIRED: Submit supporting documentation. [No further questions.] 10 Is the patient 3 months of age or older? [If no, no further questions.] 11 Does the patient have moderate-to-severe pruritus, according to prescriber? [If no, no further questions.] 12 Was the diagnosis of progressive familial intrahepatic cholestasis confirmed by genetic testing demonstrating a gene mutation affiliated with progressive familial intrahepatic cholestasis? [Note: Gene mutations affiliated with progressive familial intrahepatic cholestasis include the ATP8B1 gene, ABCB11 gene, ABCB4 gene, TJP2 gene, NR1H4 gene, and MYO5B gene.] [If no, no further questions.] 13 Does the patient have a ABCB11 variant resulting in non-functional or complete Absence of bile salt export pump protein (BSEP-3)? [If yes, no further questions.]	8	· · · · · · · · · · · · · · · · · · ·	Yes	No
patient's condition which has stabilized or improved based upon the prescriber's assessment for the following: A) Decrease in serum bile acids; B) Decrease in pruritus? ACTION REQUIRED: Submit supporting documentation. [No further questions.] 10 Is the patient 3 months of age or older? [If no, no further questions.] 11 Does the patient have moderate-to-severe pruritus, according to prescriber? Yes No [If no, no further questions.] 12 Was the diagnosis of progressive familial intrahepatic cholestasis confirmed by genetic testing demonstrating a gene mutation affiliated with progressive familial intrahepatic cholestasis? [Note: Gene mutations affiliated with progressive familial intrahepatic cholestasis include the ATP8B1 gene, ABCB11 gene, ABCB4 gene, TJP2 gene, NR1H4 gene, and MYO5B gene.] [If no, no further questions.] 13 Does the patient have a ABCB11 variant resulting in non-functional or complete absence of bile salt export pump protein (BSEP-3)? [If yes, no further questions.]		[Note: If the patient does NOT have a previously approved PA on file for the requested medication with the current plan, the renewal request will be considered under initial therapy.]		
[If no, no further questions.] 11 Does the patient have moderate-to-severe pruritus, according to prescriber? Yes No [If no, no further questions.] 12 Was the diagnosis of progressive familial intrahepatic cholestasis confirmed by genetic testing demonstrating a gene mutation affiliated with progressive familial intrahepatic cholestasis? [Note: Gene mutations affiliated with progressive familial intrahepatic cholestasis include the <i>ATP8B1</i> gene, <i>ABCB11</i> gene, <i>ABCB4</i> gene, <i>TJP2</i> gene, <i>NR1H4</i> gene, and <i>MYO5B</i> gene.] [If no, no further questions.] 13 Does the patient have a <i>ABCB11</i> variant resulting in non-functional or complete absence of bile salt export pump protein (BSEP-3)? [If yes, no further questions.]	9	patient's condition which has stabilized or improved based upon the prescriber's assessment for the following: A) Decrease in serum bile acids; B) Decrease in pruritus? ACTION REQUIRED: Submit supporting documentation.	Yes	No
 [If no, no further questions.] Was the diagnosis of progressive familial intrahepatic cholestasis confirmed by genetic testing demonstrating a gene mutation affiliated with progressive familial intrahepatic cholestasis? [Note: Gene mutations affiliated with progressive familial intrahepatic cholestasis include the <i>ATP8B1</i> gene, <i>ABCB11</i> gene, <i>ABCB4</i> gene, <i>TJP2</i> gene, <i>NR1H4</i> gene, and <i>MYO5B</i> gene.] [If no, no further questions.] Does the patient have a <i>ABCB11</i> variant resulting in non-functional or complete yes No absence of bile salt export pump protein (BSEP-3)? [If yes, no further questions.] 	10	· · · · · · · · · · · · · · · · · · ·	Yes	No
genetic testing demonstrating a gene mutation affiliated with progressive familial intrahepatic cholestasis? [Note: Gene mutations affiliated with progressive familial intrahepatic cholestasis include the <i>ATP8B1</i> gene, <i>ABCB11</i> gene, <i>ABCB4</i> gene, <i>TJP2</i> gene, <i>NR1H4</i> gene, and <i>MYO5B</i> gene.] [If no, no further questions.] 13 Does the patient have a <i>ABCB11</i> variant resulting in non-functional or complete Yes No absence of bile salt export pump protein (BSEP-3)? [If yes, no further questions.]	11	1	Yes	No
absence of bile salt export pump protein (BSEP-3)? [If yes, no further questions.]	12	genetic testing demonstrating a gene mutation affiliated with progressive familial intrahepatic cholestasis? [Note: Gene mutations affiliated with progressive familial intrahepatic cholestasis include the <i>ATP8B1</i> gene, <i>ABCB11</i> gene, <i>ABCB4</i> gene, <i>TJP2</i> gene, <i>NR1H4</i> gene, and <i>MYO5B</i> gene.]	Yes	No
	13	absence of bile salt export pump protein (BSEP-3)? [If yes, no further questions.]	Yes	No

If you have any questions, call: 1-888-258-8250

Version 07.2025



PRIOR AUTHORIZATION REQUEST

14	Does the patient have a serum bile acid concentration above the upper limit of the normal reference range for the reporting laboratory? [If no, no further questions.]	Yes	No
15	Has documentation been submitted to confirm that the patient has an intolerance, contraindication to, or failed treatment for at least 3 months with Ursodiol (ursodeoxycholic acid)? ACTION REQUIRED: Submit supporting documentation. [If no, no further questions.]	Yes	No
16	Has documentation been submitted to confirm that the patient has an intolerance, contraindication to, or failed treatment for at least 3 months with TWO different medications used for pruritus? ACTION REQUIRED: Submit supporting documentation.	Yes	No

Please document the diagnoses, symptoms, and/or any other information important to this revie	Please document the diagnoses,	symptoms,	and/or any	y other info	rmation in	nportant to	this review:
---	--------------------------------	-----------	------------	--------------	------------	-------------	--------------

SECTION B: Physician Signature

PHYSICIAN SIGNATURE

DATE

FAX COMPLETED FORM TO: 1-833-896-0656

Disclaimer: An authorization is not a guarantee of payment. Member must be eligible at the time services are rendered. Services must be a covered Health Plan Benefit and medically necessary with prior authorization as per Plan policy and procedures.

Confidentiality: The information contained in this transmission is confidential and may be protected under the Health Insurance Portability and Accountability Act of 1996. If you are not the intended recipient any use, distribution, or copying is strictly prohibited. If you have received this facsimile in error, please notify us immediately and destroy this document.

If you have any questions, call: 1-888-258-8250

Version 07.2025